key: cord-0857569-nla5rzvy
authors: García-Moguel, Ismael; Campos, Rocío Díaz; Charterina, Sergio Alonso; Rodríguez, Consuelo Fernández; Crespo, Jesús Fernández
title: COVID-19, SEVERE ASTHMA AND BIOLOGICS
date: 2020-06-14
journal: Ann Allergy Asthma Immunol
DOI: 10.1016/j.anai.2020.06.012
sha: 0b665471be397ec5f295010a53ebb52b19f48fc9
doc_id: 857569
cord_uid: nla5rzvy

nan

in the city of Wuhan and rapidly spread through the world causing a global pandemic 1 . 2 The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been 3 identified as its causal agent 1 . Factors such as older age or presence of comorbidities are 4 frequently identified as variables with a negative impact on patients' prognosis 2 . If we 5 focus on pre-existent respiratory conditions, a higher risk of developing a severe 6 infection has been reported in patients with chronic obstructive pulmonary disease 3 . 7 However, there is controversial evidence regarding the prevalence of asthma in COVID- 8 19 patients (see Table in E-Supplement) or the impact of asthma and its treatment on the 9 clinical evolution of COVID-19. 10 We report two severe asthma patients on treatment with benralizumab, an anti- 11 eosinophil monoclonal antibody that have been affected by COVID-19. 12 A 56-year-old woman who has been followed at our severe asthma unit for late-onset, 13 severe, eosinophilic asthma with bronchiectasis without criteria for Asthma-COPD 14 overlap syndrome (ACOS). Her asthma was controlled with high dose inhaled 15 corticosteroids, long-acting beta2-agonist, montelukast, ipratropium and benralizumab. 16 On March 8 th, she went to the emergency room due to a 24-hour episode of fever, 17 arthralgia, myalgia, dyspnea and brownish expectoration. On physical examination, 18 there was no wheeze. Complementary tests showed a unilobar opacity in the right lung a 19 slightly increased C reactive Protein (CRP) and lactate dehydrogenase (Table I) hydroxychloroquine were not started according to hospital´s protocol, at that moment, 24 as the patient did not have hypoxemia). The patient was discharged on the 4th day of admission due to clinical stability, which was maintained without oral corticosteroids.

One week later, the patient was asymptomatic. Four relatives also had COVID-19. 27 The other case is a 62-year-old male with severe eosinophilic asthma on treatment with 28 benralizumab since July 2018. Previously, he had received treatment with omalizumab 29 and mepolizumab both discontinued because of poor response. As comorbidities, he had 30 moderate obstructive sleep apnoea, chronic rhinosinusitis with nasal polyps, 31 bronchiectasis and obesity (body mass index 33 kg/m2). He did not fulfilled criteria of 32 ACOS. On March 25 th the patient had cough, fever and darker and thicker than his usual 33 expectoration so he self-medicated with levofloxacin 500 mg for 3 days. Due to lack of 34 improvement of symptoms, he was evaluated at primary care where a chest x-ray was 35 done that showed peripheral and bilateral opacities, more evident in mid / lower lung 36 areas, compatible with COVID-19 pneumonia ( Figure 1 ) and was referred to the 37 emergency room. One relative, who lived with him, had the same symptoms. 38 Complementary tests showed lymphopenia with increased levels of LDH, CRP, D-39 dimers, fibrinogen (Table 1) 

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

US Center for Disease Control and Prevention. Preliminary estimates of the prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 -United States

Chronic obstructive pulmonary disease is associated with severe coronavirus disease 2019 (COVID-19)

Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention (Pocket Guide, 2020 update)

COVID-19: Pandemic Contingency Planning for the Allergy and Immunology Clinic

The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15

Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells

Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2

The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease

Molecular and cellular mechanisms underlying the therapeutic effects of budesonide in asthma

Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury

Patients of COVID-19 may benefit from sustained Lopinavir-combined regimen and the increase of Eosinophil may predict the outcome of COVID-19 progression

Characteristics 13 and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State

Critically Ill Patients in the Seattle Region -Case Series

A 21 cohort of patients with COVID-19 in a major teaching hospital in Europe

Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-26

Confirmed Coronavirus Disease 2019 -COVID-NET, 14 States

Clinical 30 Characteristics of Covid-19 in New York City

Comorbidity and its 34 impact on 1590 patients with Covid-19 in China: A Nationwide Analysis

Presenting Characteristics, Comorbidities, and Outcomes Among

Hospitalized With COVID-19 in the New York City Area. JAMA. 2020: e206775

Clinical characteristics of 43 140 patients infected with SARS-CoV-2 in Wuhan